Details for New Drug Application (NDA): 213691
✉ Email this page to a colleague
NDA 213691 describes IMPEKLO, which is a drug marketed by Mylan and is included in one NDA. Additional details are available on the IMPEKLO profile page.
The generic ingredient in IMPEKLO is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
The generic ingredient in IMPEKLO is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
Summary for 213691
| Tradename: | IMPEKLO |
| Applicant: | Mylan |
| Ingredient: | clobetasol propionate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 213691
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | LOTION;TOPICAL | Strength | 0.05% | ||||
| Approval Date: | May 19, 2020 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
